The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

Abstract Background The TβRII∆k-fib transgenic (TG) mouse model of scleroderma replicates key fibrotic and vasculopathic complications of systemic sclerosis through fibroblast-directed upregulation of TGFβ signalling. We have examined peroxisome proliferator-activated receptor (PPAR) pathway perturb...

Full description

Bibliographic Details
Main Authors: Emma Derrett-Smith, Kristina E. N. Clark, Xu Shiwen, David J. Abraham, Rachel K. Hoyles, Olivier Lacombe, Pierre Broqua, Jean Louis Junien, Irena Konstantinova, Voon H. Ong, Christopher P. Denton
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Arthritis Research & Therapy
Subjects:
Systemic sclerosis
Animal models
PPAR
TGFβ
Pulmonary hypertension
Pulmonary fibrosis
Online Access:https://doi.org/10.1186/s13075-021-02592-x

Internet

https://doi.org/10.1186/s13075-021-02592-x

Similar Items